At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 779 enrolled
Drug / intervention
albiglutide +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-label, Parallel-group, Multicenter Study to Determine the Efficacy and Long-term Safety of Albiglutide Compared With Insulin in Subjects With Type 2 Diabetes Mellitus.
In Brief
A Phase 3 clinical trial evaluating albiglutide and insulin glargine for Diabetes Mellitus, Type 2. Completed, enrolled 779 participants across 337 sites in 4 countries.
Detailed Summary
A study to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesRussia, South Africa, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2009
First PostedFeb 2009
Primary CompletionJan 2012
Study CompletionMay 2013
TodayJul 2026
First PostedFeb 9, 2009
Enrollment StartFeb 1, 2009
Primary CompletionJan 1, 2012
Study CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 17.4 years ago
Interventions
albiglutidebiological
albiglutide weekly injection
insulin glarginedrug
insulin glargine